Board of Directors
SomaLogic’s Board of Directors provide critical stewardship and direction to ensuring the company’s successful realization of its mission.
Larry Gold, Ph.D.
Chairman and Founder of SomaLogic
Founder of NeXstar and Synergen
Dr. Larry Gold is the founder and Chairman of the Board, and past Chief Executive Officer of SomaLogic. Prior to SomaLogic, he founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases.
During nearly 10 years at NeXstar, Dr. Gold held numerous executive positions including Chairman of the Board, Executive Vice President of Research and Development, and Chief Science Officer. Before forming NeXagen, he also co-founded and served as co-director of research at Synergen, Inc., a pioneering biotechnology company later acquired by Amgen, Inc. Since 1970, Dr. Gold has been a professor at the University of Colorado, Boulder. While at the university, he served as the chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992.
Dr. Gold has received many citations including the CU Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, and the Chiron Prize for Biotechnology. In addition, Dr. Gold has been a member of the American Academy of Arts and Sciences since 1993 and the National Academy of Sciences since 1995.
Dr. Gold also serves on the boards of directors of CompleGen, Plato BioPharma and the Biological Sciences Curriculum Study, and is a member of the Institute for Genome Biology External Advisory Board at the University of Illinois at Urbana-Champaign.
Alister (Al) W. Reynolds
Al Reynolds joined SomaLogic as CEO in April 2017, having served on SomaLogic’s Board of Directors since 2003. He is also on the Board of Directors of Prodigo Solutions Inc., a company focused on driving savings in the healthcare supply chain.
Previously, Al served in a variety of senior executive positions for Quest Diagnostics Inc. and its predecessor company Corning Inc. for over 20 years, culminating in responsibility for the nationwide operations of Quest Diagnostics. For the past 14 years he has served on the boards and been a private investor in several successful early-phase companies, primarily in the healthcare space. Al holds a bachelor’s degree in economics from Colgate University and an MBA in finance from Cornell University.
Terry L. Randall
Vice Chairman of the Board of Mellott Company
President-CEO of Heritage Capital, LLC.
Terry Randall is currently the President-CEO of Heritage Capital, LLC (a family investment company for small and middle market enterprises) and the Vice Chairman of the Board of Mellott Company. Mr. Randall joined the Mellott Family companies in June 1997 at the request of the second-generation owners of this family-owned business. Mr. Randall has served in various executive and operational positions since 1997, including President-Chief Executive Officer.
Previously, Mr. Randall was the Managing Partner and Partner-in-Charge of the Global Group for Wolpoff & Company, LLP, Accountants and Consultants, based in Baltimore, Maryland. He joined Wolpoff in 1993 as part of the merger of Hagerstown, Maryland-based Randall & Company, LLP, Certified Public Accountants, which he founded in 1974. At Wolpoff & Company, LLP Mr. Randall handled a multitude of complex financial and management issues for clients worldwide using his understanding and comprehension of the nuances applicable to the financial posture of international companies doing business in the United States.
In 1983, Mr. Randall founded Baseball and Sports Associates, Inc. in order to acquire a minor league baseball franchise in the Carolina League located in Hagerstown, Maryland. Soon after the acquisition, a player development contract with the Baltimore Orioles led to a relationship and long-term plan to acquire additional franchises, build minor league stadiums and locate Baltimore Orioles-affiliated minor league franchises within the local television and radio market area of the Orioles in order to build the Orioles fan base and increase the value of the television and radio rights.
Mr. Randall has also served on the corporate board of directors of Tower Bancorp and its wholly owned subsidiary Graystone Tower Bank, Fairview Orchards Landbesitz, Inc., and the Carolina League of Professional Baseball and the Eastern League of Professional Baseball. He is also a re-organizing member and currently a Director and Past President of the Woodmont Chapter of the Izaak Walton League, Inc., a hunt club formed in 1870 and subsequently acquired by the Conservation Fund and the State of Maryland.
Jessica Tuchman Mathews, Ph.D.
Former President of the Carnegie Endowment for International Peace
Jessica Tuchman Mathews was appointed president of the Carnegie Endowment for International Peace in 1997. Her career includes posts in the executive and legislative branches of government, in management and research in the nonprofit arena, and in journalism.
She was a senior fellow at the Council on Foreign Relations from 1993 to 1997 and served as director of the Council’s Washington program. While there, she published her seminal 1997 Foreign Affairs article, “Power Shift,” chosen by the editors as one of the most influential in the journal’s 75 years.
From 1982 to 1993, Dr. Mathews was founding vice president and director of research of the World Resources Institute, an internationally known center for policy research on environmental and natural-resource management issues.
She served on the editorial board of the Washington Post from 1980 to 1982, covering energy, environment, science, technology, arms control, health and other issues. Later, she became a weekly columnist for the Washington Post, writing a column that appeared nationwide and in the International Herald Tribune.
From 1977 to 1979, Dr. Mathews was director of the Office of Global Issues of the National Security Council, covering nuclear proliferation, conventional arms sales policy, chemical and biological warfare and human rights. In 1993, she returned to government as deputy to the Undersecretary of State for Global Affairs.
Dr. Mathews is a director of SomaLogic Inc., HanesBrands Inc., and the Union of Concerned Scientists, and a trustee of the Nuclear Threat Initiative and the International Crisis Group. She is also a member of the Council on Foreign Relations and the American Philosophical Society. She has previously served on the boards of the Brookings Institution, Radcliffe College, the Rockefeller Brothers Fund, the Century Foundation, the Surface Transportation Policy Project and the Joyce Foundation, among others.
The Carnegie Endowment for International Peace is a private, nonprofit organization dedicated to advancing cooperation between nations and promoting active international engagement by the U.S. Founded in 1910, its work is nonpartisan and dedicated to achieving practical results. The Endowment has added operations in Beijing, Beirut and Brussels to its longstanding offices in Washington, D.C. and Moscow as part of its transformation into the first global think tank.
Dr. Mathews has a bachelor’s degree from Radcliffe College and her Ph.D. from the California Institute of Technology.
Charles M. Lillis, Ph.D.
Founder and Managing Partner of LoneTree Capital
Former Chairman and CEO of Media One Group
In addition to SomaLogic, Inc., Dr. Lillis serves on the boards of several public and privately owned companies, including SuperValu Inc., the nation’s 10th largest food retailer and Medco Health Solutions, Inc., the nation’s largest PBM. He is also co-founder and managing partner of LoneTree Capital, a private equity group that invests primarily in the communications and information industry and a founding member of Castle Pines Capital, a specialized channel finance provider.
Prior to his board activities, Dr. Lillis served as chairman and CEO of Media One Group, Inc., from 1997 to 2000 and as CEO from 1995 to 1997. He was also dean of the College of Business at the University of Colorado from 1984 to 1985 and professor of business at Washington State University from 1972 to 1980.
Dr. Lillis holds a bachelor’s degree and an M.B.A from the University of Washington and a Ph.D. in business from the University of Oregon.
Takayuki Shiratsuchi, Ph.D.
Operating Officer, General Manager of Basic Research, Otsuka Pharmaceutical Co., Ltd.
Takayuki Shiratsuchi is an Operating Officer and General Manager of Basic Research at Otsuka Pharmaceutical Co., Ltd., a Japan-based, global pharmaceutical company that focuses on pharmaceutical products for the treatment of diseases, and nutraceutical products for the maintenance of everyday health. In this role he is responsible for all basic research at the company.
From 2011 through January 2015, Takayuki was Chief Operating Officer and then Chief Executive Officer of Otsuka Maryland Medicinal Laboratories (OMML), Otsuka’s main research institute in the US. Earlier, Takayuki was a researcher and a director in various research institutes at Otsuka. His research and managerial engagement spanned oncology, immunology, vaccinology, molecular biology and genetics.
At the University of Tokyo, Takayuki earned a bachelor’s degree, a master’s degree from the Graduate School of Pharmaceutical Sciences and a Ph.D. from the Graduate School of Medicine.